Narrow search
Showing 1 - 10 of 19,860
Cover Image
Pharmaceutical M&A activity : effects on prices, innovation, and competition
Richman, Barak; Mitchell, Will; Vidal, Elena; Schulman, … - 2017
The rise of blockbuster pharmaceutical acquisitions has prompted fears that unprecedented market concentration will weaken competition. Two of the most prominent concerns focus on the upstream and downstream ends of the pharmaceutical industry: (1) the concern that these mergers will concentrate...
Persistent link: https://www.econbiz.de/10011721586
Cover Image
Private versus social incentives for pharmaceutical innovation
González, Paula; Macho-Stadler, Inés; … - 2015
We provide a theoretical framework to contribute to the current debate regarding the tendency of pharmaceutical companies to direct their R&D toward marketing products that are "follow-on" drugs of already existing drugs, rather than toward the development of breakthrough drugs. We construct a...
Persistent link: https://www.econbiz.de/10011406575
Cover Image
Have pharmaceutical R&D project success rates decreased? : a critical review and new empirical results
Backfisch, Martin - 2017 - Version: 30 October 2017
In the context of the ongoing debate about an innovation crisis in the pharmaceutical industry, we study the success …
Persistent link: https://www.econbiz.de/10011773501
Cover Image
Dynamic mergers effects on R&D investments and drug development across research phases in the pharmaceutical industry
Siebert, Ralph; Tian, Zhili - 2020
Pharmaceutical firms spend increasing amounts in mergers and acquisitions (M&As), which raises the question of whether sufficient investment is left after mergers to further develop firms' internal drug development capability. We evaluate the effects of M&As on firms' post-merger R&D...
Persistent link: https://www.econbiz.de/10012219372
Cover Image
The impact of the entry of biosimilars : evidence from Europe
Scott Morton, Fiona; Stern, Ariel D.; Stern, Scott - 2017
Persistent link: https://www.econbiz.de/10011708133
Cover Image
Evaluating the US pharmaceutical patent policy
Izhak, Olena; Saxell, Tanja; Takalo, Tuomas - 2021
The debate on whether COVID-19 vaccine patents are slowing down the pace of vaccination and the recovery from the crisis has brought the optimal design of pharmaceutical patent policy to the fore. In this paper we evaluate patent policy in the US pharmaceutical industry. We estimate the effect...
Persistent link: https://www.econbiz.de/10012802183
Cover Image
Optimal patent policy for pharmaceutical industry
Izhak, Olena; Saxell, Tanja; Takalo, Tuomas - 2020
Persistent link: https://www.econbiz.de/10012439514
Cover Image
The impact of R&D cooperations on drug variety offered on the market : evidence from the pharmaceutical industry
Banerjee, Tannista; Siebert, Ralph - 2014
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
Cover Image
Many are called, few are chosen: the role of science in drug development decisions
Colen, Linde; Belderbos, René; Kelchtermans, Stijn; … - 2022
Persistent link: https://www.econbiz.de/10013541933
Cover Image
The effect of intellectual property rights on domestic innovation in the pharmaceutical sector
Gamba, Simona - 2016
This paper analyses the causal impact of Intellectual Property Rights (IPR) on pharmaceutical innovation in a panel of …. Domestic innovation is measured as citation-weighted domestic patents filed at the European Patent Office (EPO): to account for … to patent at the EPO. Results show that, in the short-run, IPR stimulate innovation. The effect for developing countries …
Persistent link: https://www.econbiz.de/10011509446